| Protocol | In Vitro | In vitro activity: Desmopressin (also known as DDAVP) is a synthetic octapeptide and an analogue of the human antidiuretic hormone arginine vasopressin. Vasopressin is a hormone that reduces the production of urine and desmopressin is a synthetic version for vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor. Desmopressin is most frequently prescribed for treatment of diabetes insipidus or nocturnal enuresis. Kinase Assay: Cell Assay: HUVECs are transduced with recombinant adenoviruses AdV2R.EGFP (AdV2R) or AdlacZ. 3 days later cells are incubated for 25 min with 1 μM DDAVP or 10 μM forskolin, both in presence of IBMX. Cell extracts are analyzed for eNOS Ser1177 phosphorylation and eNOS expression. |
|---|
| In Vivo | DDAVP (2 μg/kg) reduces accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibits tumor progression in animals surgically implanted in the spleen with CT-26 cells, and causes some reduction in liver metastasis. DDAVP is able to inhibit lung colonization by blood-borne breast cancer cells in an experimental murine model. It dramatically reduces lymph node and lung metastasis in a model of mammary tumor manipulation and surgical excision in mice when administered perioperatively, and also exerts antitumor effects in combination with chemotherapy. DDAVP increases the plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator, and also enhances platelet adhesion to the vessel wall. |
|---|
| Animal model | Syngeneic adult male Balb/c mice inoculated with CT-26 colon cancer cells |
|---|
These protocols are for reference only. InvivoChem does not
independently validate these methods.
Preparing Stock Solutions
| Solvent volume to be added |
Mass (the weight of a compound) |
| Mother liquor concentration |
1mg | 5mg | 10mg | 20mg |
| 1mM | 0.9353 mL | 4.6763 mL | 9.3526 mL | 18.7052 mL |
|---|
| 5mM | 0.1871 mL | 0.9353 mL | 1.8705 mL | 3.7410 mL |
|---|
| 10mM | 0.0935 mL | 0.4676 mL | 0.9353 mL | 1.8705 mL |
|---|
| 20mM | 0.0468 mL | 0.2338 mL | 0.4676 mL | 0.9353 mL |
|---|
|
Quality Control Documentation
|
|
: 
